文献速递生殖医学

HMG与重组FSH加重组LH在IVF卵巢刺激中的比较:LH来源是否重要?

HMG versus recombinant FSH plus recombinant LH in ovarian stimulation for IVF: does the source of LH preparation matter?
PubMed 文献 · Reprod Biomed Online · 2019-09-11

本文综述比较了HMG(含HCG来源LH活性)与重组FSH加重组LH(含LH来源LH活性)在IVF卵巢刺激中的效果。现有研究多为观察性,每日剂量和给药方式不同;两组卵巢刺激变量及临床妊娠率、活产率无统计学显著差异,汇总分析未得出明确倾向性结论,需进一步大型RCT。

要点

  • HMG与重组FSH加重组LH在卵巢刺激变量上无统计学显著差异。
  • 两组临床妊娠率和活产率无统计学显著差异。
  • 现有证据不足以推荐任一LH来源,需大型RCT进一步研究。

核心结论

  • 现有证据未显示HMG与重组FSH加重组LH在卵巢刺激变量及IVF结局上有统计学显著差异。
  • 汇总所有前瞻性和回顾性研究的联合分析未得出支持任一LH生物活性来源的明确结论。

研究设计与样本

  • 文献综述,纳入报告使用HMG或重组FSH加重组LH进行卵巢刺激后IVF和ICSI治疗结局的相关文章。
  • 现有研究多为观察性,使用不同的每日剂量和给药方式。

主要发现

  • HMG与重组FSH加重组LH比较,卵巢刺激变量无统计学显著差异。
  • HMG与重组FSH加重组LH比较,临床妊娠率和活产率无统计学显著差异。
  • 联合分析所有前瞻性和回顾性研究未得出支持任一LH生物活性来源的明确结论。

关键数值与推荐

  • HMG提供HCG来源的LH生物活性,重组FSH加重组LH提供LH来源的LH生物活性。
  • 现有研究使用不同的每日剂量和给药方式。

临床怎么用

  • 现有证据不足以支持在卵巢刺激中优先选择HMG或重组FSH加重组LH中的任一LH来源。
  • 需进一步大型随机对照研究探讨LH来源对IVF结局的影响并识别最可能从添加LH生物活性补充中获益的患者。

局限性

  • 现有研究多为观察性,使用不同的每日剂量和给药方式。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Studies on the role of LH supplementation in patients undergoing assisted reproductive technique use different sources of LH bioactivity-containing preparations, daily doses and modes of administration. This review aims to critically present the available evidence comparing the effect of the two commercially available LH preparations (human menopausal gonadotrophin [HMG] and recombinant FSH + recombinant LH) with different sources of intrinsic LH bioactivity (HCG versus LH, respectively) on ovarian stimulation characteristics and IVF cycle outcomes. A literature review was conducted for all relevant articles reporting on IVF and intracytoplasmic sperm injection treatment outcome after ovarian stimulation using HMG or recombinant FSH plus recombinant LH. The available studies are mostly observational, using different daily doses and modes of administration. No statistically significant differences were observed in ovarian stimulation variables and clinical pregnancy and live birth rates when HMG was compared with recombinant FSH + recombinant LH. Moreover, combined analysis of all the available prospective and retrospective studies produced no firm conclusions in favour of either source of LH bioactivity. Further large randomized controlled studies are needed to investigate the effect of the LH source on IVF outcome and to identify patients who are most likely to benefit from the addition of LH bioactivity supplementation.

来源:Reprod Biomed Online,查看原文。版权归原作者所有。

引用

  1. Orvieto R. HMG versus recombinant FSH plus recombinant LH in ovarian stimulation for IVF: does the source of LH preparation matter? Reprod Biomed Online. 2019. PMID: 31672439. doi:10.1016/j.rbmo.2019.08.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。